The purpose of this study is to assess the benefit of 177Lu-DOTATATE versus interferon α-2b
in patients with progressive, unresectable, non-pancreatic gastrointestinal neuroendocrine
tumors resistant to therapy with somatostatin analogues, in terms of disease control.
Phase:
Phase 3
Details
Lead Sponsor:
Jules Bordet Institute
Treatments:
Interferon alpha-2 Interferon-alpha Interferons Lutetium Lu 177 dotatate Octreotide